Engineering of a femtomolar affinity binding protein to human serum albumin.
about
Early implementation of QbD in biopharmaceutical development: a practical exampleFusion to a highly stable consensus albumin binding domain allows for tunable pharmacokineticsThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapyDesired alteration of protein affinities: competitive selection of protein variants using yeast signal transduction machineryEngineering bispecificity into a single albumin-binding domain.Bacterial display in combinatorial protein engineering.Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G.Slow, reversible, coupled folding and binding of the spectrin tetramerization domain.A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expressionExtending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion proteinInhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversificationNovel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of actionThe albumin-binding domain as a scaffold for protein engineering.Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity.Phage display selection of tight specific binding variants from a hyperthermostable Sso7d scaffold protein library.Albumin-binding domain conjugate for near-infrared fluorescence lymphatic imaging.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingBiodistribution of a bispecific single-chain diabody and its half-life extended derivatives.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.Protein scaffold-based molecular probes for cancer molecular imaging.Performance limitations for nanowire/nanoribbon biosensors.Albumin and its application in drug delivery.Half-life extended biotherapeutics.Biocompatible Size-Defined Dendrimer-Albumin Binding Protein Hybrid Materials as a Versatile Platform for Biomedical Applications.Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.The future of protein scaffolds as affinity reagents for purification.Bioconjugation - using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.Serum albumin as a local therapeutic agent in cell therapy and tissue engineering.Affibody molecules as engineered protein drugs.Identification of proteins that specifically recognize and bind protofibrillar aggregates of amyloid-β.Half-life extension using serum albumin-binding DARPin® domains.An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells.An enzymatic advance in nicotine cessation therapy.Intramolecular thioether crosslinking of therapeutic proteins to increase proteolytic stability.In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor.
P2860
Q26830466-880478A6-D5B8-49A4-9370-AE17CC7A62D3Q27701821-50FA26C6-4A1A-4E55-80E9-10CF82EE87FEQ28257521-01B01A57-78FE-4E50-99E4-BCAC4D7FD8BAQ28543140-084CC93D-C7AB-48AA-864D-B860DFF18357Q31032588-2BB14A9A-2806-4685-A846-D717F1D184E5Q33970172-1B44E686-AAFF-465E-8B14-5EEA2C54809BQ34082509-39DCC7CC-959D-4C72-AE17-342B9A01FFE2Q34314714-48228791-95D2-48EF-B677-3B5CE363C404Q34435496-4A241510-8E00-406C-BE5B-07D44288F93BQ34568391-C4810D2C-52D7-412D-973F-810FE22308E8Q34661388-D68628B0-A2B2-4293-A5AF-8D766604788DQ34722687-FF6461FA-3E79-4642-8FBB-EBB677ABC82AQ35087618-FBC11448-BF0D-495A-A375-76DC68C6E144Q35136577-D6FBC338-BA14-4EB4-ABA9-B260EF230867Q35525772-1D30059C-5635-4CDB-8F02-3968E2D0B5DAQ35694115-B61D10E8-F5C3-4D85-9AC7-2FB72B9A6C1DQ35911849-2A2CE518-1091-40E4-A7A7-0F8FFC2915E9Q35942344-8DC0065E-D0BC-4801-8778-54771821EFC2Q37138332-84C0A09D-81AB-47DB-9063-1BAF08B2740CQ37377633-6B151F55-8D1D-428A-83FF-0300850658F0Q37660979-CFA81292-EBBC-4150-8B2E-0D2525586AF9Q37696357-56A07FC9-1B76-48F6-9B94-D909579DE480Q38125143-63DF1804-B7E0-4546-A6D2-08CF93D31A9FQ38292087-E3778D5C-C8B3-4F08-9399-4CDFF899B86EQ38770067-262EA5AF-E228-4D1A-A2E7-F8271974E797Q38805312-A7C21F61-1A6B-4D55-A43C-869A3F16ADFDQ38820756-B0E3952D-B205-47CA-8EC6-C9C8BF8E14EBQ38827102-3CFD0B4D-F371-4AD6-864F-167AD347122AQ38909537-E4F16CFB-D6F6-4D3A-9686-DBBB82A81587Q38931171-96C12D61-D079-424F-94C9-B92EE862B455Q38989309-3C4F8059-863C-4B5F-9799-D274CAAF738AQ39010656-0F306416-7825-438B-B4EE-6A5F53AAFBCAQ39012336-06F31D12-59FC-4575-B77C-7C323701F63EQ39197528-BE628CD5-2E79-4FCA-8CF7-739F957002DBQ41074877-80C0D4D7-568B-41E6-9582-865436372DF8Q46271471-BAF6D767-D469-404D-ABEE-D420A784FBBDQ47155614-CC22AEFD-65B3-4BF0-83D3-762992D12E06Q47199097-9E517370-57EC-490F-881A-D35DE5E5A121Q51055585-F377F8F1-5143-49BA-B64C-B5B710EC53B7Q51735710-11341571-AD6B-4909-A5E7-61E693807079
P2860
Engineering of a femtomolar affinity binding protein to human serum albumin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Engineering of a femtomolar affinity binding protein to human serum albumin.
@ast
Engineering of a femtomolar affinity binding protein to human serum albumin.
@en
type
label
Engineering of a femtomolar affinity binding protein to human serum albumin.
@ast
Engineering of a femtomolar affinity binding protein to human serum albumin.
@en
prefLabel
Engineering of a femtomolar affinity binding protein to human serum albumin.
@ast
Engineering of a femtomolar affinity binding protein to human serum albumin.
@en
P2093
P2860
P356
P1476
Engineering of a femtomolar affinity binding protein to human serum albumin.
@en
P2093
Andreas Jonsson
Lars Abrahmsén
Nina Herne
P2860
P304
P356
10.1093/PROTEIN/GZN028
P577
2008-05-22T00:00:00Z